Ziopharm stops enrolment in Phase II sarcoma trial early on positive data
This article was originally published in Scrip
Executive Summary
Ziopharm Oncology has stopped enrolment early in a randomised Phase II trial testing its intravenous chemotherapy drug palifosfamide (Zymafos, ZIO-201) in advanced sarcoma on positive interim data. The US company plans to initiate a registration trial, as early as the first half of next year, following regulatory review of the palifosfamide programme to date.